-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cathie Wood's Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling. -- Barrons.com
Cathie Wood's Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling. -- Barrons.com
By Jack Denton
Crispr Therapeutics stock was tumbling Wednesday, after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors.
That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs).
The ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) cumulatively bought up hundreds of thousands of shares of Crispr (ticker: CRSP) in the week leading up to its release of trial data on its gene-edited cancer drug, CTX110.
Crispr said Tuesday that "encouraging" phase-one results of the drug meant the company planned to expand its trial, with the next stage potentially leading to data for submission to regulators for approval.
But investors appeared underwhelmed by the results, which showed that just 36% of the 26 patients who received the drug had a complete response with no detectable cancer.
Crispr stock was down 6% in U.S. premarket trading Wednesday, as investors fretted over how the drug may fare against competitors. Shares rose in rival gene-editing biotechs like Editas Medicine (EDIT), which was 0.3% higher in the premarket, and Allogene Therapeutics (ALLO), which ticked up 0.2%.
Leading up to the release of Crispr's results, Wood's investment group bought up more than 700,000 Crispr shares valued around $100 each, according to Cathie's Ark, a website tracking ARK trades.
ARKK snapped up more than 513,000 shares of Crispr in trades made Oct. 8, Oct. 11, and Oct. 12, while ARKG bought more than 201,000 shares in trades on Oct. 8 and Oct. 11, according to data from Cathie's Ark.
Ark's holdings in the biotech group represented a market capitalization of $7.8 billion based on the stock's closing price Tuesday of $102.59.
After stunning performances in 2020, when ARKK's net asset value (NAV) grew 152% and ARKG's NAV surged 180%, both funds have failed to match the performance in 2021. ARKK's NAV is up 5% so far this year, while ARKG's NAV has declined 0.8%.
Write to Jack Denton at jack.denton@dowjones.com
By Jack Denton
傑克·丹頓(Jack Denton)著
Crispr Therapeutics stock was tumbling Wednesday, after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors.
週三,CRISPR治療公司的股票暴跌,此前這家基於基因的醫學專家的一項實驗性治療結果令投資者印象不佳。
That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs).
這對知名投資者凱西·伍德(Cathie Wood)來説是個壞消息,她的方舟投資管理公司(Ark Investment Management)最近為其兩隻積極管理的交易所交易基金(ETF)購買了這家生物技術公司的股票。
The ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) cumulatively bought up hundreds of thousands of shares of Crispr (ticker: CRSP) in the week leading up to its release of trial data on its gene-edited cancer drug, CTX110.
方舟創新ETF(ARKK)和方舟基因革命ETF(ARKG)在Crispr(股票代碼:CRSP)公佈其基因編輯抗癌藥物CTX110的試驗數據前一週累計買入數十萬股。
Crispr said Tuesday that "encouraging" phase-one results of the drug meant the company planned to expand its trial, with the next stage potentially leading to data for submission to regulators for approval.
CRISPR週二表示,該藥物的第一階段結果“令人鼓舞”,這意味着該公司計劃擴大試驗範圍,下一階段可能會產生數據,提交監管機構審批。
But investors appeared underwhelmed by the results, which showed that just 36% of the 26 patients who received the drug had a complete response with no detectable cancer.
但投資者似乎對結果不以為然,結果顯示,在接受藥物治療的26名患者中,只有36%的人完全有效,沒有發現癌症。
Crispr stock was down 6% in U.S. premarket trading Wednesday, as investors fretted over how the drug may fare against competitors. Shares rose in rival gene-editing biotechs like Editas Medicine (EDIT), which was 0.3% higher in the premarket, and Allogene Therapeutics (ALLO), which ticked up 0.2%.
CRISPR的股價週三在美國盤前交易中下跌6%,投資者擔心這種藥物可能會如何對抗競爭對手。競爭對手基因編輯生物技術公司的股價上漲,如Editas Medicine(EDIT)和Allo(Allo),前者在盤前上漲0.3%,後者上漲0.2%。
Leading up to the release of Crispr's results, Wood's investment group bought up more than 700,000 Crispr shares valued around $100 each, according to Cathie's Ark, a website tracking ARK trades.
根據追蹤方舟交易的網站Cathie‘s Ark的數據,在Crispr公佈財報之前,伍德的投資集團買入了超過70萬股Crispr股票,每股價值約100美元。
ARKK snapped up more than 513,000 shares of Crispr in trades made Oct. 8, Oct. 11, and Oct. 12, while ARKG bought more than 201,000 shares in trades on Oct. 8 and Oct. 11, according to data from Cathie's Ark.
根據凱茜方舟的數據,Arkk在10月8日、10月11日和10月12日的交易中搶購了超過51.3萬股Crispr股票,而ARKG在10月8日和10月11日的交易中購買了超過20.1萬股Crispr股票。
Ark's holdings in the biotech group represented a market capitalization of $7.8 billion based on the stock's closing price Tuesday of $102.59.
按照該股週二102.59美元的收盤價計算,方舟在這家生物科技集團的持股相當於78億美元的市值。
After stunning performances in 2020, when ARKK's net asset value (NAV) grew 152% and ARKG's NAV surged 180%, both funds have failed to match the performance in 2021. ARKK's NAV is up 5% so far this year, while ARKG's NAV has declined 0.8%.
2020年Arkk的資產淨值(NAV)增長152%,ARKG的資產淨值飆升180%,在經歷了令人驚歎的表現後,這兩隻基金在2021年的表現都未能與之匹敵。Arkk的資產淨值今年迄今上漲了5%,而ArkG的資產淨值下降了0.8%。
Write to Jack Denton at jack.denton@dowjones.com
寫信給傑克·丹頓(Jack Denton),電子郵件:jack.denton@dowjones.com
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧